Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

Journal of Clinical Investigation

Volumn 103, Issue 2, 1999, Pages 159-165

  Benjamin, Laura E ^a   Golijanin, Dragan ^b   Itin, Ahuva ^a   Pode, Dov ^b   Keshet, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; ANDROGEN; ANTIANDROGEN; FLUTAMIDE; GOSERELIN; TETRACYCLINE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMATURITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSGENE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM;

EID: 0032952010     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5028     Document Type: Article

References (34)

1. Folkman, J. 1997. Cancer: principles and practice of oncology. Lippincott-Raven Publishers. Philadelphia, PA. 3075-3085.
2. Holmgren, L., O'Reilly, M.S., and Folkman, J. 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:149-153.
3. Millauer, B., et al. 1996. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1615-1620.
4. Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A., and Ferrara, N. 1995. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95:1789-1797.
5. Borgstrom, P., Hillan, K.J., Sriramarao, P., and Ferrara, N. 1996. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56:4032-4039.
6. Yuan, F., et al. 1996. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA. 93:14765-14770.
7. Borgstrom, P., Bourdon, M.A., Hillan, K.J., Sriramarao, P., and Ferrara, N. 1998. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 35:1-10.
8. O'Reilly, M.S., et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277-285.
9. O'Reilly, M.S., et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [comment]. Cell. 79:315-328.
10. O'Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-692.
11. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M.S. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:404-407.
12. Denekamp, J. 1993. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy [review]. Br. J. Radiol. 66:181-196.
13. Alon, T., et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1:1024-1028.
14. Benjamin, L., Hemo, I., and Keshet, E. 1998. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 125:1591-1598.
15. Dumont, D.J., et al. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:1897-1909.
16. Puri, M.C., Rossant, J., Alitalo, K., Bernstein, A., and Partanen, J. 1995. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:5884-5891.
17. Sato, T.N., et al. 1995. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:70-74.
18. Suri, C., et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [comment]. Cell. 87:1171-1180.
19. Carmeliet, P., et al. 1996. Role of tissue factor in embryonic blood vessel development. Nature. 383:73-75.
20. Leveen, P., et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 8:1875-1887.
21. Lindahl, P., Johansson, B.R., Leveen, P., and Betsholtz, C. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:242-245.
22. Soriano, P. 1994. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 8:1888-1896.
23. Franck-Lissbrant, I., Haggstrom, S., Damber, J.-E., and Bergh, A. 1988. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated rats. Endocrinology. 139:451-456.
24. Jackson, M.W., Bentel, J.M., and Tilley, W.D. 1997. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol. 157:2323-2328.
25. Ferrer, F.A., et al. 1998. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology. 51:161-167.
26. Jain, R.K., et al. 1998. Endothelial cell death, angiogenesis and microvascular function following castration in an androgen-dependent tumor: role of VEGF. Proc. Natl. Acad. Sci. USA. 181:10820-10825.
27. Benjamin, L.E., and Keshet, E. 1997. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA. 94:8761-8766.
28. Pe'er, J., et al. 1995. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72:638-645.
29. Papandreou, C.N., et al. 1998. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. 4:50-57.
30. English, H., Drago, J., and Santen, R. 1985. Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiographic and morphometrical analysis. Prostate. 7:41-51.
31. Joseph, I.B., and Isaacs, J.T. 1997. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res. 57:1054-1057.
32. Rak, J., Filmus, J., and Kerbel, R. 1996. Reciprocal paracrine interactions between tumour cells and endothelial cells: the "angiogenic progression" hypothesis. Eur. J. Cancer. 32A:2438-2450.
33. Brooks, P.C., Clark, R.A., and Cheresh, D.A. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:569-571.
34. Friedlander, M., et al. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1500-1502.